Remote preconditioning therapy for newly sick sepsis patients
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether a “remote preconditioning” treatment given during early sepsis can help protect the kidneys and improve outcomes. It is for adults in the ICU very soon after sepsis begins.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- Your sepsis started within the last 12 hours.
- You are in the ICU and need a breathing machine for at least 24 hours and/or medicines to raise blood pressure (vasopressors).
- You can receive full ICU care and are expected to stay in the ICU for at least 72 hours.
- You have not been diagnosed with kidney injury before starting the study, and you do not have severe long-term kidney disease (eGFR below 30).
- You are not pregnant or breastfeeding, and you are able to give consent in writing (or consent is obtained according to study rules).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a simple “arm cuff” treatment done before a heart artery procedure can help protect the kidneys and the heart in people with congestive heart failure. If it works, it may lower the chance of kidney injury around the time of the scan/stent procedure.
This study tests a new way to diagnose kidney problems in people with sepsis using a special bedside ultrasound. The goal is to catch early signs of kidney damage so treatment can start sooner.
This trial looks at acute kidney injury that can happen during sepsis (a serious body-wide infection or suspected infection). It may help improve how doctors detect and manage kidney problems early, especially in intensive care or around major surgery.
This trial tests a special device that filters parts of the blood to calm inflammation in people with severe acute kidney injury in the ICU. It may help improve recovery and reduce complications by “deactivating” certain immune cells.
This trial tests if a new drug, AZD4144, can help people with sepsis-related acute kidney injury in the ICU. It aims to see if the drug can improve kidney recovery and reduce complications.
This trial tests if adding an iron chelator (MEX-CD1) to the dialysis fluid can help remove harmful iron from the blood in patients with sepsis-related acute kidney injury who need continuous dialysis. It may reduce damage to the kidneys and other organs.
Hear when a new Critically Ill trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.